LSU Medical Center

Neuroscience Center of Excellence on the occasion of the opening of the new Research Laboratories

Academic Lecture
March 17, 1998
10:30 a.m.
1st Floor, Medical Education Building, Lecture Room B

Open House and Reception
March 17, 1998
12:00 p.m.
8th Floor, LSU-Lions Clinic

New Orleans, Louisiana
In 1988, I was honored with the responsibility of building a comprehensive Neuroscience Center at the LSU Medical Center in New Orleans. It thrills my colleagues and me to tell you about the opening of the research laboratories that serve the people of Louisiana and beyond. Our new research laboratories will contribute to the enhancement of academic excellence at the LSU Medical Center, strengthen fundamental neurosciences and facilitate the transfer of major breakthroughs into the clinical arena. It will be the site of several educational and community outreach activities.

Our research teams are guided by a quest for knowledge and a common desire to help end the suffering caused by Alzheimer’s Disease, blinding eye diseases, stroke, Parkinson’s Disease, mental depression and other diseases of the brain and nervous system. These scientists are smartly pursuing intensive research that is key to unlocking the mystery of how and why these diseases occur.

The Neuroscience Center of Excellence is the state’s only interdisciplinary program that incorporates behavioral, clinical and basic neurosciences. This synergy in science is leading to the development of a new drug that may help prevent the death of brain cells. It has also led to the development of a new analgesic drug that can eliminate pain without masking potentially dangerous postsurgical fever. These are just a few of our exciting research breakthroughs.

The most important component of research institutions is the people: our powerful and imaginative team continues to break new ground in understanding the nervous system. Our most recent additions to the team are Dr. Rene Anand (from the University of Pennsylvania), Dr. Jeffrey Erickson (from the National Institutes of Health), and Dr. Jeffrey Magee (from the Baylor College of Medicine).

With our solid academic programs serving as the foundation, the Center has established a preeminent reputation as a center of learning and discovery. Our interdisciplinary Ph.D. Program is shaping the future of the neurosciences by ensuring that new generations of scientists and clinicians have the depth and breadth of knowledge necessary to advance medical science. Other activities include annual scientific retreats, cooperative research initiatives, effective and extensive faculty development, incentive grant awards and a Seminar Series for faculty, fellows, residents and students at the LSU Medical Center. As a global resource for other scientists and physicians, this collaborative environment fosters the exchange of information and ideas that is essential to scientific progress. Outreach is also a critical part of our mission to help the community-at-large understand neurological and psychiatric diseases.

As we approach the new millennium, and as I look back and reflect upon our efforts to combat some of the most devastating diseases known to humankind, I am pleased with the progress we have made. But we cannot rest on our laurels. Although we have made great strides in our efforts to understand the most challenging frontier in medical science – the human brain – much remains to be done!

Support for the Neuroscience Center came from many sources. Monies from the Department of Defense and the State of Louisiana were particularly important for the construction of this facility. But everyone in our community should take great pride in the creation of the LSU Neuroscience Center of Excellence. Medical science progresses because people dedicate themselves to finding new solutions to complex conditions and because they are afforded the resources necessary to carry out their research. You shared our vision. You lent your mind, your voice and your support. You made this happen.

The opening of the Neuroscience Center of Excellence Research Laboratories is a promise of renewed persistence, dedication and hard work toward the understanding of how the brain functions, how diseases affect the brain and for advancing the discovery of new treatments for neurological and psychiatric diseases.

Thank you for offering assistance and hope to those suffering from these devastating diseases. And thank you for helping us remain at the forefront as we enter into our next century of discovery.

Sincerely,

Nicolas G. Bazan, M.D., Ph.D.
Ernest C. and Yvette C. Villere Professor, Boyd Professor
Director, LSU Neuroscience Center of Excellence
Program

Master of Ceremonies

Mervin L. Trail, M.D.
Chancellor
LSU Medical Center

10:30 a.m.
Academic Lecture
1st Floor, Medical Education Building, Lecture Room B

Sir John Vane, FRS,
Nobel Laureate in Medicine or Physiology
The Mechanism of Action of Anti-Inflammatory Drugs

12:00 p.m.
Press Conference and Media Tour
8th Floor, LSU-Lions Clinic

Mervin L. Trail, M.D.
Chancellor
LSU Medical Center

Sir John Vane, FRS,
Nobel Laureate in Medicine or Physiology

Timothy P. Ryan, Ph.D.,
Dean
College of Business Administration
University of New Orleans

Nicolas G. Bazan, M.D., Ph.D.
Ernest C. and Yvette C. Villere Professor
Boyd Professor
Director, Neuroscience Center of Excellence

Reception immediately following
Sir John Vane has had a distinguished career in both academia and industry. After receiving his bachelor’s and doctorate in pharmacology from Oxford, he pursued academic research at Oxford and Yale University. He received the Nobel Prize in Physiology or Medicine in 1982, which he shared with Sune K. Bergstrom and Bengt Samuelsson, for his work in prostaglandins and for discovering the mode of action of aspirin. He is highly regarded for his continuing research in the areas of cardiovascular disease and chronic inflammation.

He spent eighteen years as a research scientist at the Royal College of Surgeons of England, the last seven of which were as Professor of Experimental Pharmacology. As a consultant to Squibb, he was the father of the company’s angiotensin converting enzyme programme which led to the blockbusting drug, Captopril. During his twelve years as Group research and Development Director at the Wellcome Foundation Ltd., he oversaw the development of a number of innovative drugs including Tracrium, Flolan, Zovirax and Lamictal.

In 1986, Sir John moved to St. Bartholomew’s Hospital Medical School to found an Institute of Cardiovascular Research. In 1990, the Institute was awarded charity status. It is now amongst the top twenty medical charities in the UK and distributes more than £2M per annum mostly to the medical college. Through its scientific publications and presentations at meetings, the Institute has established itself as an internationally recognized center of excellence in science, especially in pharmacology. Over the last twelve years, it has trained many students, including more than 40 doctorates awarded and 33 more Ph.D.’s in training.

In 1991, Sir John, with his colleague, Professor Anggard, incorporated a new pharmaceutical company which they called Vanguard Medica Ltd. It’s purpose is to develop compounds which the pharmaceutical industry have put on one side, not because of toxicity but because of changes in the Company’s direction or in priorities. There were six founding directors, all long-standing friends of Sir John and all ex-R&D directors from the drug industry. Under the direction of a CEO, Mr. Robert Mansfield, the company flourished and was successfully floated on the London Stock Exchange in May 1996 with a paper capital value of £150 million.

He now acts as a consultant to several pharmaceutical and biopharmaceutical companies and is a board member of some. Sir John became a Fellow of the Royal Society in 1974, was knighted in 1984 and has received many other honorary fellowships and doctorates.

Sir John Vane has published numerous review articles and over 750 papers on pharmacology and related topics. His other scientific activities include membership of the British Pharmacological Society, the Physiological Society, the Society for Drug Research, and the Royal Society.

1961-1984 Fulfilled various offices for the British Pharmacological Society
1985-1987 Member of Council and Vice-President, the Royal Society
1985-1992 Member of Council of the Imperial Cancer Research Fund
1994- Non-executive Chairman of the Technology Transfer Company of the Imperial Cancer Research Fund
1987-1993 Member of Scientific Advisory Committee for the Osaka Biosciences Institute, Japan
1993- Chairman of the Biomedical Research Educational Trust
Sir John Vane has had a distinguished career in both academia and industry. After receiving his bachelor’s and doctorate in pharmacology from Oxford, he pursued academic research at Oxford and Yale University. He received the Nobel Prize in Physiology or Medicine in 1982, which he shared with Sune K. Bergstrom and Bengt Samuelsson, for his work in prostaglandins and for discovering the mode of action of aspirin. He is highly regarded for his continuing research in the areas of cardiovascular disease and chronic inflammation.

He spent eighteen years as a research scientist at the Royal College of Surgeons of England, the last seven of which were as Professor of Experimental Pharmacology. As a consultant to Squibb, he was the father of the company’s angiotensin converting enzyme programme which led to the blockbusting drug, Captopril. During his twelve years as Group research and Development Director at the Wellcome Foundation Ltd., he oversaw the development of a number of innovative drugs including Tracrium, Flolan, Zovirax and Lamictal.

In 1986, Sir John moved to St. Bartholomew’s Hospital Medical School to found an Institute of Cardiovascular Research. In 1990, the Institute was awarded charity status. It is now amongst the top twenty medical charities in the UK and distributes more than £2M per annum mostly to the medical college. Through its scientific publications and presentations at meetings, the Institute has established itself as an internationally recognized center of excellence in science, especially in pharmacology. Over the last twelve years, it has trained many students, including more than 40 doctors awarded and 33 more Ph.D.’s in training.

In 1991, Sir John, with his colleague, Professor Anggard, incorporated a new pharmaceutical company which they called Vanguard Medica Ltd. It’s purpose is to develop compounds which the pharmaceutical industry have put on one side, not because of toxicity but because of changes in the Company’s direction or in priorities. There were six founding directors, all long-standing friends of Sir John and all ex-R&D directors from the drug industry. Under the direction of a CEO, Mr. Robert Mansfield, the company flourished and was successfully floated on the London Stock Exchange in May 1996 with a paper capital value of £150 million.

He now acts as a consultant to several pharmaceutical and biopharmaceutical companies and is a board member of some. Sir John became a Fellow of the Royal Society in 1974, was knighted in 1984 and has received many other honorary fellowships and doctorates.

Sir John Vane has published numerous review articles and over 750 papers on pharmacology and related topics. His other scientific activities include membership of the British Pharmacological Society, the Physiological Society, the Society for Drug Research, and the Royal Society.

1961-1984 Fulfilled various offices for the British Pharmacological Society
1985-1987 Member of Council and Vice-President, the Royal Society
1985-1992 Member of Council of the Imperial Cancer Research Fund
1994- Member of Council of the Imperial Cancer Research Fund
1987- Non-executive Chairman of the Technology Transfer Company of the Imperial Cancer Research Fund
1987-1993 Member of Scientific Advisory Committee for the Osaka Biosciences Institute, Japan
1993- Chairman of the Biomedical Research Educational Trust
Allen A. Copping, D.D.S.
President
LSU System

Mervin L. Trail, M.D.
Chancellor
LSU Medical Center

Robert L. Marier, M.D., M.H.A.
Dean
LSU School of Medicine

Nicolas G. Bazan, M.D., Ph.D.
Ernest C. and Yoette C. Villere Professor,
Boyd Professor
Director, Neuroscience Center of Excellence
LSU Neuroscience Center
Advisory Committee*

Roger Beuerman, PhD
Professor of Ophthalmology,
Cell Biology and Anatomy and Psychiatry
Director of Summer Undergraduate
Neuroscience Program

Richard Bobbin, PhD
Professor of Otorhinolaryngology
Lions-Kresge Hearing Research Laboratory

Michael Carey, MD
Professor of Neurosurgery

Larry Carver, MD
Professor of Psychiatry and Neuroscience
Co-Director, Brain Tissue Bank

Prescott Deindinger, PhD
Professor of Biochemistry
and Molecular Biology

Herbert E. Kaufman, MD
Boyd Professor and Head of Ophthalmology
Professor of Pharmacology
and Experimental Therapeutics
Director, LSU Eye Center

Bronya Keats, PhD
Professor of Biometry and Genetics

David G. Kline, MD
Boyd Professor and Chairman
of Neurosurgery

Kenneth Kratz, PhD
Professor of Cell Biology and Anatomy
Assistant Director,
LSU Neuroscience Center of Excellence

Iris Lindberg, PhD
Professor of Biochemistry
and Molecular Biology

James May, PhD
Ernest C. and Yvette C. Villere
Professor of Neuroscience
Department of Psychology
University of New Orleans

R. Ranney Mize, PhD
Professor and Chairman of Cell Biology
and Anatomy
Co-Director of the Interdisciplinary
Ph.D. Program in Neuroscience

Joseph M. Moerschbaecher, PhD
Professor and Chairman of Pharmacology
and Experimental Therapeutics

Howard J. Osofsky, MD
Professor and Head of Psychiatry

Jayaraman Rao, MD
Carl Baldridge Professor of Neurology
and Neuroscience
Director, Parkinson's Disease and
Movement Disorders Center
Co-Director, Brain Tissue Bank

Robert Roskoski, Jr., MD, PhD
Brazda Professor and Head of
Biochemistry and Molecular Biology

Diane Smith, PhD
Professor of Cell Biology and Anatomy

Austin J. Sumner, MD
Richard M. Paddison, MD Professor
and Head of Neurology
Professor of Neuroscience

Cheryl Weill, PhD
Professor of Neurology

* All of these faculty members are jointly appointed in the Neuroscience Center

LSU Neuroscience Center Community Advisory Committee

E. Johann Bultman
Edward L. Diefenthal
Nancy Diefenthal
Paul Nalty, Esq.
E. Paige Sensenbrenner, Esq.